We report that cryoablation of primary tumors synergizes with anti-CTLA-4 treatment to mediate rejection of secondary tumors in the TRAMP mouse model of prostate cancer. T cells, in particular CD8 + T cells specific for the TRAMP antigen SPAS-1, were enriched in both secondary tumors and spleens of combination-treated mice.
The recently FDA approved immunotherapy, Ipilimumab (commercial name Yervoy) is a fully human monoclonal antibody that blocks the function of CTLA-4, an inhibitory receptor expressed by T cells. CTLA-4 is expressed and trafficked to the T-cell surface upon activation, and blockade of this checkpoint pathway, through administration of monoclonal antibodies, induces antitumor immunity by promoting T-cell survival and proliferation. 1 In clinical trials, Ipilimumab improved overall survival time of metastatic melanoma patients compared with control groups. 2, 3 Studies in mouse models, using a monoclonal antibody that blocks the function of mouse CTLA-4, showed that treatment with CTLA-4 blockade as a single agent results in the rejection of immunogenic tumors. 4 However, rejection of less immunogenic tumors can be achieved only when CTLA-4 blockade is combined with immunotherapies such as those that induce increased antigen uptake and presentation on MHC Class I molecules (a process called "crosspresentation") by professional antigenpresenting cells (APCs). These types of therapies include GM-CSF secreting whole tumor cell vaccines, 5 radiation 6 or a FLT-ligand expressing vaccine. 7 It is reasonable to hypothesize that in humans, similar combination therapies administered in conjunction with Ipilimumab may boost their effectiveness and increase survival time in a larger fraction of patients. While this hypothesis is currently being tested in clinical trials combining the use of a GM-CSF-expressing tumor cell vaccine (GVAX) with Ipilimumab, 8 we wanted to investigate whether this was also true when anti-CTLA-4 was combined with tumor ablation techniques. Local tumor ablation, such as cryoablation, has occasionally been shown to lead regression of tumor metastases, a phenomenon that could likely be attributed to a systemic anti-tumor immune response resulting from increased, albeit in most cases still insufficient, antigen cross-presentation by professional APC. Starting from the assumption that cryoablation would increase cross-presentation, we hypothesized that administration of anti-CTLA-4 during the destruction of a primary tumor, through cryoablation, would further improve the generation a systemic immune response that would result in the eradication of metastatic disease. 9 The possibility of combining anti-CTLA-4 therapy with cryotherapy is appealing because of the low morbidity and cost-effectiveness of such an ablative technique compared with surgical interventions.
Using the transplantable TRAMP model of mouse prostate cancer, we developed a unique system to study the induction of systemic immunity and rejection of a secondary tumor challenge in mice treated with anti-CTLA-4 and cryoablation combination therapy. Our previous work in the TRAMP model led to the discovery of the CD8 + T-cell tumor antigen SPAS-1, which contains a mutation in its antigenic epitope.
10 SPAS-1 was identified as the target of a T cell line derived from the spleen and lymph nodes of mice that received a tumor-rejecting immunotherapy: anti-CTLA-4 and GM-CSF-expressing TRAMP cell vaccine. By this method, SPAS-1 was defined due to its highly immunogenic character and was found to be the immunodominant TRAMP antigen. This finding has enabled us to track the specific CD8 + T-cell response in the TRAMP model through the use of MHC Class I tetramers and ELISPOT assays. TRAMP C2 tumors were implanted on the left flank of male mice and cryoablated when they reached about 5-8 mm in diameter. The mice were then treated with anti-CTLA-4 and rechallenged with a second inoculation of TRAMP C2 on the opposite flank. Strikingly, in mice that received both anti-CTLA-4 and cryoablation, the number of SPAS-1-specific CD8 + T cells per mg of tumor was significantly increased compared with control mice. Furthermore, the SPAS-1-specific T cells Although the full mechanism of tumor immunity in our model has not been elucidated, it likely involves the exertion of effector function of TRAMP-specific T cells after their activation by activated APCs. Neither cryoablation nor CTLA-4 blockade on their own were sufficient to mediate rejection of secondary tumors (Fig. 1) . Therapies such as vaccines, chemotherapies, and radiotherapy that improve antigen cross-presentation may be the most effective treatments to combine with CTLA-4 blockade and we speculate that cryoablation synergizes with CTLA-4 blockade by augmenting antigen cross-presentation. Another possible mechanism is that while a growing intact tumor is likely to have a low level of antigen release in the absence of cryoablation, removal of the primary tumor may result in the removal of a systemic immune suppressive environment. While future studies will delineate the mechanisms by which cryoablation cooperates with CTLA-4 blockade to generate systemic immunity, our current work provides evidence that this combination therapy may improve survival in patients with metastatic disease. 
